ClinicalTrials.gg
CompletedNCT00770562Updated Oct 22, 2014Results posted

A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

A Phase 3 interventional study of rituximab and Dexamethasone in Idiopathic Thrombocytopenic Purpura, sponsored by Hoffmann-La Roche. Completed at 22 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-22.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. Rituximab · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
9th of 27
103 · median 60
Started
2005
the only one that year
Phase 3
8 of 27
2 open now
Registered
9th of 27
by date
Lead sponsor
2 of 27
Hoffmann-La Roche

Among the 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic, this one is the 9th largest by enrollment, is the only one that started in 2005, is one of 8 in phase 3, and was the 9th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

This study will compare the efficacy, safety, and pharmacokinetics of standard treatment versus standard treatment plus MabThera in patients with ITP. The anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients >=18 years of age;
  • untreated ITP.

Exclusion criteria

Exclusion Criteria:

  • ITP with relapse;
  • positive test result for or or C;
  • active infection requiring systemic therapy;
  • within 3 years before study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Active comparator
    Dexamethasone

    Participants received 40 milligrams (mg) dexamethasone, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than or equal to (≤)20 x 10\^9 platelets per liter (L; from Day 30 up to end of 6 months) were treated with salvage treatment of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg per square meter (mg/m\^2), intravenously (IV), with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28.

    Drug: Dexamethasone

  • Experimental
    Dexamethasone plus Rituximab

    Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m\^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (\<) 20 x10\^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m\^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.

    Drug: rituximab · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Sustained Response

    Sustained response defined as a platelet count of greater than or equal to (≥) 50x10\^9/L at 6 months (Week 24) after the initial treatment. Participants failing therapy before Month 6 (Week 24) and treated in other ways were considered failures.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With an Initial Response

    Initial response was defined as an increase in platelet count of ≥50x10\^9/L by Day 30 (Week 4) after the start of treatment in either treatment arm.

    Time frame: Week 4

  2. Percentage of Participants With an Initial Complete Response

    Initial complete response was defined as an increase in platelet count of ≥100x10\^9/L by Day 30 (Week 4) after the initiation of treatment in either treatment arm.

    Time frame: Week 4

07

Results

Posted Oct 22, 2014

Participant flow

Participant flow — Overall Study
MilestoneArm A: DexamethasoneArm B: Dexamethasone + Rituximab
Started5350
Completed5249
Not completed11
Withdrew: Did not take treatment11

Outcome measures

PrimaryPercentage of Participants With a Sustained Response

Sustained response defined as a platelet count of greater than or equal to (≥) 50x10\^9/L at 6 months (Week 24) after the initial treatment. Participants failing therapy before Month 6 (Week 24) and treated in other ways were considered failures.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Sustained Response
percentage of participantsArm A: DexamethasoneArm B: Dexamethasone + Rituximab
Percentage of Participants With a Sustained Response3663
Statistical analysis
  • Arm A: Dexamethasone vs Arm B: Dexamethasone + Rituximab · Fisher Exact · p = 0.004
SecondaryPercentage of Participants With an Initial Response

Initial response was defined as an increase in platelet count of ≥50x10\^9/L by Day 30 (Week 4) after the start of treatment in either treatment arm.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With an Initial Response
percentage of participantsArm A: DexamethasoneArm B: Dexamethasone + Rituximab
Percentage of Participants With an Initial Response2768
Statistical analysis
  • Arm A: Dexamethasone vs Arm B: Dexamethasone + Rituximab · Fisher Exact · p = 0.001
SecondaryPercentage of Participants With an Initial Complete Response

Initial complete response was defined as an increase in platelet count of ≥100x10\^9/L by Day 30 (Week 4) after the initiation of treatment in either treatment arm.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With an Initial Complete Response
percentage of participantsArm A: DexamethasoneArm B: Dexamethasone + Rituximab
Percentage of Participants With an Initial Complete Response2348
Statistical analysis
  • Arm A: Dexamethasone vs Arm B: Dexamethasone + Rituximab · Fisher Exact · p = 0.015

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Dexamethasone—1/52 (1.9%)25/52 (48.1%)
Arm B: Dexamethasone + Rituximab—3/49 (6.1%)37/49 (75.5%)
Salvage Therapy—3/27 (11.1%)18/27 (66.7%)
Most frequent serious events
Most frequent serious events
EventArm A: DexamethasoneArm B: Dexamethasone + RituximabSalvage Therapy
Platelet count decreasedBlood and lymphatic system disorders0/520/491/27
ConvulsionNervous system disorders0/520/491/27
SeizureNervous system disorders0/520/491/27
TIANervous system disorders0/520/491/27
Hemorrhagic syndrome and low plateletBlood and lymphatic system disorders0/520/491/27
Hemorrhage syndromeBlood and lymphatic system disorders0/521/490/27
Supraventricular tachycardiaCardiac disorders0/521/490/27
Interstitial pneumoniaInfections and infestations0/521/490/27
Rib fractureInjury, poisoning and procedural complications1/520/490/27
Most frequent other events
Showing 10 of 114
Most frequent other events
EventArm A: DexamethasoneArm B: Dexamethasone + RituximabSalvage Therapy
PyrexiaGeneral disorders1/5210/495/27
Abdominal pain upperGastrointestinal disorders1/527/492/27
HeadacheNervous system disorders3/526/492/27
CoughRespiratory, thoracic and mediastinal disorders5/526/490/27
DiarrhoeaGastrointestinal disorders0/525/490/27
AstheniaGeneral disorders2/525/490/27
NasopharyngitisInfections and infestations2/524/490/27
PetechiaeSkin and subcutaneous tissue disorders4/520/491/27
LeukopeniaBlood and lymphatic system disorders0/520/492/27
ConstipationGastrointestinal disorders1/521/492/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: DexamethasoneArm B: Dexamethasone + RituximabTotal
Mean47 ± 1949 ± 1648.41 ± 18.03
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: DexamethasoneArm B: Dexamethasone + RituximabTotal
Female332760
Male192241
08

Study locations

22 sites
  • Bari, 70124, Italy
  • Bologna, 40138, Italy
  • Brescia, 25123, Italy
  • Cagliari, 09121, Italy
  • Cuneo, 12100, Italy
  • Genova, 16132, Italy
  • Milano, 20162, Italy
  • Napoli, 80131, Italy
  • Padova, 35128, Italy
  • Palermo, 90146, Italy
  • Pavia, 27100, Italy
  • Pesaro, 61100, Italy
  • Pescara, 65100, Italy
  • Ravenna, 48100, Italy
  • Reggio Emilia, 42100, Italy
  • Roma, 00133, Italy
  • Roma, 00161, Italy
  • Roma, 00168, Italy
  • Siena, 53100, Italy
  • Taranto, 74100, Italy
  • Udine, 33100, Italy
  • Verona, 37130, Italy
09

References and documents

Publications

  • Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010 Apr 8;115(14):2755-62. doi: 10.1182/blood-2009-07-229815. Epub 2010 Feb 3. PubMed 20130241 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 6 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 10, 2008
Start
Jul 2005
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Oct 22, 2014
Last update
Oct 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00770562
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 10, 2008
Start date
Jul 2005
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Oct 22, 2014
Last update
Oct 22, 2014

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion